| scholarly article | Q13442814 |
| P2093 | author name string | H Ogawa | |
| K Inoue | |||
| H Sugiyama | |||
| M Nakagawa | |||
| T Yamagami | |||
| K Kita | |||
| H Miwa | |||
| T Masaoka | |||
| K Nasu | |||
| A Hiraoka | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3071-3079 | |
| P577 | publication date | 1994-11-01 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia | |
| P478 | volume | 84 |
| Q40226406 | A 4-gene expression score associated with high levels of Wilms Tumor-1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia |
| Q38714821 | A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity. |
| Q64084045 | A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemothe |
| Q36782669 | A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients |
| Q33849643 | A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia |
| Q26773907 | Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer |
| Q89424441 | Aberrant expression of ETS1 and ETS2 proteins in cancer |
| Q27026836 | Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials |
| Q91768661 | Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin |
| Q39117761 | Acute myeloid leukemia targets for bispecific antibodies |
| Q28087291 | Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia |
| Q38739446 | An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. |
| Q33567270 | Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection |
| Q90363521 | Antileukemic Cell Proliferation of Active Compounds from Kaffir Lime (Citrus hystrix) Leaves |
| Q35817394 | Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis. |
| Q37384745 | Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide |
| Q53092142 | Biased usage of T cell receptor β-chain variable region genes of Wilms' tumor gene (WT1)-specific CD8+ T cells in patients with solid tumors and healthy donors. |
| Q53950598 | Biology and modulation of multidrug resistance (MDR) in hematological malignancies. |
| Q34476278 | CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells |
| Q34820068 | Cancer immunotherapy targeting WT1 protein |
| Q37132892 | Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation |
| Q95723920 | Clinical Impact of Overexpression of FOXP3 and WT1 on Disease Outcome in Egyptian Acute Myeloid Leukemia Patients |
| Q80464844 | Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia |
| Q50279411 | Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood |
| Q80532937 | Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma |
| Q74169459 | Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination |
| Q93065274 | DNA Methylation Readers and Cancer: Mechanistic and Therapeutic Applications |
| Q51632377 | Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities. |
| Q43297784 | Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia |
| Q37420778 | Dendritic cell-based immunotherapy for myeloid leukemias. |
| Q34616701 | Detection and preliminary characterization of CD8+T lymphocytes specific for Wilms' tumor antigen in patients with non-Hodgkin lymphoma. |
| Q33587590 | Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice |
| Q36009181 | Diagnostic value of Wilms tumor 1 and CD44 in Langerhans cell sarcoma: case series of 4 patients |
| Q79451366 | Different kinetics of WT1 and PML-RARalpha gene expression levels during remission induction therapy with all-trans retinoic acid alone in acute promyelocytic leukemia |
| Q36143489 | Dmp1 and tumor suppression |
| Q35553621 | Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation |
| Q44925953 | Down-regulation of Wilms' tumor 1 expression in glioblastoma cells increases radiosensitivity independently of p53. |
| Q36021773 | Down-regulatory mechanism of mammea E/BB from Mammea siamensis seed extract on Wilms' Tumor 1 expression in K562 cells |
| Q53193906 | Downregulation of the WT1 gene expression via TMPyP4 stabilization of promoter G-quadruplexes in leukemia cells. |
| Q33732862 | EFFECT OF THAI SARAPHI FLOWER EXTRACTS ON WT1 AND BCR/ABL PROTEIN EXPRESSION IN LEUKEMIC CELL LINES. |
| Q38326365 | Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth |
| Q40298442 | Feasibility of gene-immunotherapy using WT1-specific T-cell receptor gene transfer for infant acute lymphoblastic leukemia with MLL gene rearrangement |
| Q34341142 | G1 phase arrest induced by Wilms tumor protein WT1 is abrogated by cyclin/CDK complexes |
| Q36574157 | Heterogeneity in the molecular pathogenesis of paroxysmal nocturnal hemoglobinuria (PNH) syndromes and expansion mechanism of a PNH clone |
| Q37567685 | Homology modeling and molecular dynamics studies of Wilms' tumor gene 1 frameshift mutations in exon 7. |
| Q35203507 | Hypoxia-sensitive epigenetic regulation of an antisense-oriented lncRNA controls WT1 expression in myeloid leukemia cells |
| Q35897592 | Identification of Novel HLA-A*24:02-Restricted Epitope Derived from a Homeobox Protein Expressed in Hematological Malignancies |
| Q49370276 | Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia |
| Q34421127 | Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells |
| Q92637440 | Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments |
| Q30482686 | In silico regulatory analysis for exploring human disease progression |
| Q35332017 | Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population |
| Q37535549 | Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression |
| Q34068404 | Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination |
| Q39197772 | Interaction of human genes WT1 and CML28 in leukemic cells |
| Q92913685 | Intraocular infiltration of Philadelphia chromosome-positive acute lymphoblastic leukemia diagnosed by polymerase chain reaction from the aqueous humor: A case report |
| Q33584244 | K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate |
| Q43724885 | Lethal adenovirus infection in a patient who had undergone nonmyeloablative stem cell transplantation |
| Q33491557 | Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemia |
| Q36384606 | Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. |
| Q42050372 | Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine |
| Q47862030 | Methods of Detection of Measurable Residual Disease in AML. |
| Q44699907 | Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1). |
| Q55078512 | Mutation analysis of the WT1 gene in myelodysplastic syndromes. |
| Q92996721 | Not Only Mutations Matter: Molecular Picture of Acute Myeloid Leukemia Emerging from Transcriptome Studies |
| Q26753160 | Novel Molecular Markers for Breast Cancer |
| Q40973052 | Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. |
| Q33648713 | Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6 |
| Q58576859 | Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: a prospective clinical phase I/II trial |
| Q85343128 | Prognostic impact of WT1 expression prior to hematopoietic stem cell transplantation in children with malignant hematological diseases |
| Q47247980 | Quantification of Wilms' tumor 1 mRNA by digital polymerase chain reaction. |
| Q91643038 | Reader-free ELISPOT assay for immuno-monitoring in peptide-based cancer vaccine immunotherapy |
| Q34861985 | Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation |
| Q73033628 | Removal of known, abundant cDNA species by specific double-stranded cDNA synthesis-based subtraction |
| Q34612637 | Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. |
| Q38362636 | Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies |
| Q41279759 | Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia |
| Q34618828 | Single nucleotide polymorphisms in the Wilms' tumour gene 1 in clear cell renal cell carcinoma |
| Q42617564 | Studies of Wilms' Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore |
| Q39974686 | TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels. |
| Q37659113 | Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. |
| Q42800235 | The Wilms tumor protein is persistently associated with the nuclear matrix throughout the cell cycle |
| Q34077533 | The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells |
| Q34478581 | The Wilms' Tumor Gene WT1 - 17AA/- KTS Splice Variant Increases Tumorigenic Activity Through Up-Regulation of Vascular Endothelial Growth Factor in an In Vivo Ovarian Cancer Model |
| Q42193837 | The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy |
| Q42165091 | The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells |
| Q35224361 | The molecular genetics of hematologic malignancies |
| Q34261346 | The possible role and application of WT1 in human leukemia |
| Q34820049 | The role of WT1 in oncogenesis: tumor suppressor or oncogene? |
| Q47388677 | The transcriptional coregulator NAB2 is a target gene for the Wilms' tumor gene 1 protein (WT1) in leukemic cells |
| Q33636990 | The translation elongation factor eEF2 is a novel tumor‑associated antigen overexpressed in various types of cancers. |
| Q21195233 | The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells |
| Q88965519 | Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers |
| Q33992114 | Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein |
| Q47147990 | Timing Is Everything: Combining Post-Transplantation Adoptive Cell Therapy and Tumor Vaccines |
| Q34719237 | Transcriptional regulation of myelopoiesis |
| Q35838113 | Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings |
| Q58609591 | Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network |
| Q37848203 | Tumour-associated antigens: considerations for their use in tumour immunotherapy. |
| Q50971977 | Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis. |
| Q41894404 | Update on optimal management of acute myeloid leukemia |
| Q88990865 | Utilization of Wilms' tumor 1 antigen in a panel for differential diagnosis of ovarian carcinomas |
| Q34079458 | WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology Group |
| Q38826671 | WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma |
| Q33239524 | WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study |
| Q54331723 | WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups. |
| Q39937224 | WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia |
| Q38395134 | WT1 protein expression in astrocytic tumors and its relationship with cellular proliferation index |
| Q39323696 | WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells |
| Q82808308 | WT1(235), a ninemer peptide derived from Wilms' tumor gene product, is a candidate peptide for the vaccination of HLA-A*0201-positive patients with hematopoietic malignancies |
| Q37635023 | WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions |
| Q34820008 | Wilms tumor gene (WT1) expression as a panleukemic marker |
| Q73743100 | Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis |
| Q34261302 | Wilms' tumor gene WT1: its oncogenic function and clinical application |
| Q35095712 | Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene |
| Q64953132 | shRNA-WT1 Potentiates Anticancer Effects of Gemcitabine and Cisplatin Against B16F10 Lung Metastases In Vitro and In Vivo. |
Search more.